Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Q2 FY27 Earnings Presentation
32 slides from Ind-swift Laboratories's earnings presentation, Nov 4, 2026
Slide 1: Exchange filing cover letter for investor presentation
Ref: ISLL:CH:2026 Date: 4th November, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mu
Slide 2: Investor Presentation Q2 & H1 FY27
Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer INVESTOR PRESENTATION Q2 & H1 FY27 | Results for the period ended 30 September 2026 1
Slide 3: Management Commentary
MANAGEMENT COMMENTARY “Q2FY27 is a strong validation of the strategic choices we made earlier. Our transition from an API manufacturer to a focused FDF manufacturer, and the scale-up of operations on that platform, is now clearly visible in our performance. Operating income grew over 50% year-on-yea
Slide 4: Evolution & Transformation Journey
EVOLUTION & TRANSFORMATION JOURNEY Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories In
Slide 5: Ind-Swift Laboratories – The Before State
IND - SWIFT LABORATORIES LTD – “The Before State” DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers L
Slide 6: Transaction Summary & Financial Reset
TRANSACTION SUMMARY & FINANCIAL RESET Synthimed Labs Transaction Summary Strategic Rationale Slump Sale : Transaction Value : Debt Elimination: Proceeds used to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile t
Slide 7: Post-Transformation Overview
POST - TRANSFORMATION OVERVIEW Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 900+ 540+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Product registration Years of (Effective 31 March
Slide 8: Manufacturing Infrastructure
MANUFACTURING INFRASTRUCTURE Domestic Unit Global Business Unit (GBU) Derabassi, Punjab Samba, J&K • Strategic Status: 100% Export-Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Capabilities: Dedicated blocks for Oral Solid Dosages (Tablets, Capsules, Sachets). •
Slide 9: R&D Capabilities
R&D CAPABILITES Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 70+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validati
Slide 10: R&D Molecule Launch Pipeline FY27 to FY30
R&D MOLECULE LAUNCH PIPELINE FY27 TO FY30 FY27 TO FY30 A forward-looking portfolio of planned product launches across key therapy areas 2028-29 11 MOLECULES 2029-30 2 MOLECULES Rosuvastatin Spironolactone Mirabegron PR CARDIOVASCULAR CARDIOVASCULAR UROLOGY Sacubitril + Valsartan CARDIOVASCULAR Rifax
Slide 11: Integrated Business Lines
INTEGRATED BUSINESS LINES Infrastructure International& Capabilities Engine (Global Business Unit) Domestic Engine (India Operations) Focus: High-Value Exports & Regulated Market Comprehensive Market Coverage via multiple Strategic Verticals • Dossier-driven model for regulated & semi-regulated mark
Slide 12: Diversified Markets & Clientele
DIVERSIFIED MARKETS & CLIENTELE 47% Europe 4% Canada 2% 4% C.I.S. Middle East 1% 18% 2% Mexico South East Asia FWA 3% UAE 5% 10% 3% Africa Australia LATAM 1% South Africa 11
Slide 13: Territory-wise Export Sales Performance
TERRITORY - WISE EXPORT SALES PERFORMANCE Q2 FY27 Export mix across Contract Manufacturing and Own Brands UAE 0.89 South Africa 1.81 S.E.A. 10.45 Middle East 8.55 Mexico 2.83 LATAM 1.78 FWA 4.2 Europe 22.83 29.5 Canada 2.33 C.I.S. 0.61 Australia 5.75 4.34 Africa 4.13 Contract Manufacturing Own Brand
Slide 14: Global Market Potential
GLOBAL MARKET POTENTIAL 80 Global CMO Market Overview (In USD Billions) 73.75 70 2024 2030 60 56.09 51.91 50 40 30.88 30 20 15.73 10.48 9 10 6.65 2.13 3.6 2.03 3.99 0.83 1.33 0 UAE South Africa Australia Middle East Canada Europe USA Source Source Source Source Source Source Source • High demand for
Slide 15: Global Product Registrations
GLOBAL PRODUCT REGISTRATIONS 116 CIS + 9 Russia 11 Canada 170 Europe 47 GCC 51 UAE 177 South East Asia 209 Africa + FWA 209 Africa + FWA 177 South East Asia 86 Latin America 116 CIS + 9 Russia 86 Latin America 51 UAE 170 Europe 34 Australia 34 Australia 47 GCC 19 South Africa 11 Canada 6 New 6 New Z
Slide 16: Product Registrations Expected in 2026
PRODUCT REGISTRATIONS EXPECTED IN 2026 - 27 Number of products registration expected, by region 333 TOTAL PRODUCT REGISTRATIONS EXPECTED IN 2026-27 Canada 1 Europe 18 Central Asia 21 Middle East 17 S.E.A. 144 Africa + FWA 109 Products registration expected 109 Africa + FWA 4 Australia Australia 4 La
Slide 17: Global Regulatory Landscape
GLOBAL REGULATORY LANDSCAPE Russia Canada United Germany Hungary Kingdom Geneva Hessen Afghanistan UAE Saudi Taiwan Oman Thailand India Cambodia Kenya Nigeria Uganda Emerging Markets WHO-GMP (Geneva). South Africa Australia MoH UAE. Regulated Markets MoH Russia. UK-MHRA (United Kingdom). MoH Oman TG
Slide 18: Operational & Strategic Developments – Q2FY27
OPERATIONAL & STRATEGIC DEVELOPMENTS – Q2FY27 CDMO/ Own Brands Commercialized: CDMO partnerships/ Own brands with major CDMO partners have been commercialized and are expected to contribute incremental revenue of ₹100-130 Cr in FY27. New Product Readiness: Commercial validation of Clarithromycin Dry
Slide 19: Top Export Portfolio Mix
TOP EXPORT PORTFOLIO MIX Market Size Market Size Top Product Revenue Wise Breakup Products FY25 FY26 2024/25 2030-35 Source FY26 (INR Lakhs) (In USD Billions) (In USD Billions) Atorvastatin 4795.71 8549.74 11.86 19.09 Link 5.56% 5.89% Ezetimibe + 22.17% 2328.13 8077.82 3.5 5.6 Link 2.25% Atorvas 4.3
Slide 20: Quarterly Sales Breakup Segment Wise
QUARTERLY SALES BREAKUP SEGMENT WISE 60.00% 56.72% 55.75% 50.00% 40.00% 30.00% 26.99% 26.64% 20.00% 10.00% 6.84% 6.41% 6.62% 5.43% 5.00% 3.61% 0.00% Branded Generics Ethical Division Contract Manufacturing (P2P) Own-Brands Contract Manufacturing Domestic Export Q1FY27 Q2FY27 19
Slide 21: Upcoming Product Launch
UPCOMING PRODUCT LAUNCH Projected Products Market Commercialization Market Size Market Size Source Revenue Year 2024/5 (In USD Mn) 2030 (In USD Mn) (In USD Mn) Ibuprofen Sachet Europe 12.00 Commercialized 112.7 164.1 Link Commercial Clarithromycin Dry Europe 6.00 Validation 2152.2 3501.43 Link Suspe
Slide 22: Key Catalyst & Initiatives
KEY CATALYST & INITIATIVES Global Demand Surge Domestic Consumption Boom • Global pharmaceutical market expected to reach • Indian pharma market projected to reach from USD 55 USD 2,350 Billion by 2030. Source Billion USD 130 Billion by 2030, CAGR 12.25%. Source • Strong generic drug demand across r
Slide 23: Growth Rationale / Future Outlook
GROWTH RATIONALE / FUTURE OUTLOOK • CDMO Partnership Commercialized • Commercial supplies begin in 2026, • Topline CAGR 20-25%, scaling from ₹100-130 Cr incremental revenue ₹636 Cr to ₹1,500+ Cr by FY30. expected in FY27. • CDMO to deliver ₹200 to 220 Cr over 2 years, driven by commercial Greenfield
Slide 24: Board of Directors
BOARD OF DIRECTORS Mr. N.R. Munjal Mr. Himanshu Jain Chairman and Whole Time Director Managing Director (Domestic Operations) • 40+ years of experience expanding the Group’s • 22+ years of experience specializing in project footprint across 85+ countries with offices in planning, financial strategy,
Slide 25: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM Mr. Varun Chabra Mr. Ravi Bhardwaj President – International Mr. Pardeep Verma Mr. Gagan Agarwal VP Corporate Affairs & CS Chief Financial Officer Corporate Quality Head Marketing • 35+ Years of Experience across • 25+ years exp, expanded Quality, formulation R&D & • 29+ ye
Slide 26: Key Financial Metrics (Standalone)
KEY FINANCIAL METRICS (STANDALONE) Total Revenue (INR Cr.) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%) EBITDA Margins (%) 242.49 35. 00 31.03 42.33 45. 00 30. 00 40. 00 24.44 33.32 25. 00 35. 00 193.71 30. 00 13.21% 20. 00 25. 00 18.02% 13.13% 174.91 14.94 20. 00 18.69 15. 0
Slide 27: Key Financial Metrics (Standalone) H1
KEY FINANCIAL METRICS (STANDALONE) Total Revenue (INR Cr) Operating EBITDA (INR Cr) & Operating PAT (INR Cr) & PAT Margins (%), excluding EBITDA Margins (%) Exc. Items 60. 00 500 .00 80. 00 75.65 55.47 450 .00 436.20 70. 00 50. 00 400 .00 60. 00 350 .00 330.87 40. 00 50. 00 13.18% 300 .00 17.97% 30.
Slide 28: Q2 FY27 Standalone Financial Highlights
Q2 FY27 STANDALONE FINANCIAL HIGHLIGHTS Particulars (INR Cr) Q4 FY26 Q1 FY27 Q2FY27 Q-o-Q Change (%) Revenue 164.72 186.12 230.23 Operating other income 7.98 -0.03 4.66 Non operating other income 2.21 7.63 7.60 Total Revenue 174.91 193.71 242.49 25.18 Raw material expense 64.86 75.21 106.04 Employee
Slide 29: H1 FY27 Standalone Financial Highlights
H1 FY27 STANDALONE FINANCIAL HIGHLIGHTS Particulars (INR Cr) H1 FY26 H1 FY27 Y-o-Y Change (%) Revenue 298.43 416.35 Operating other income 11.58 4.63 Non operating other income 20.86 15.23 Total Revenue 330.87 436.20 31.83 Raw material expense 148.50 181.26 Employee benefit expense 67.73 76.32 Other
Slide 30: Standalone Balance Sheet
STANDALONE BALANCE SHEET Equities & Liabilities (INR Cr) H1 FY26 H1 FY27 Assets (INR Cr) H1 FY26 H1 FY27 Shareholder's Fund Non Current Assets Share Capital 81.61 86.96 PP&E 282.84 309.61 Reserves & Surplus 1217.04 1373.62 CWIP 0.00 41.82 Total Equity 1298.66 1460.59 Deferred tax assets 44.63 50.34
Slide 31: Stock Data
STOCK DATA As on 02-11-2026 Stock Performance From 1st Apr 2025 To 30th Oct 2026 BSE: Stock Price ₹ 367.40 450 1000000 Market Capitalization ₹ Crs 3,194.97 Volume Close 8,69,61,5 400 900000 No. of Share Outstanding 58 800000 Face Value ₹ 10.00 350 52 Week High ₹ 426.00 700000 300 52 Week Low ₹ 87.00
Slide 32: Thank You
Thank You ```` Investor & Public Relations Consultant Ind Swift Laboratories Ltd. SCO 850, NAC, Shivalik Enclave, 103-8, Lodha Eternis, MIDC, Manimajra, Chandigarh, Andheri East, Mumbai 400093 1600101, India Maharashtra, India. Phone: +91 9814131627 Phone: +91 85911 45959 Email: investor@indswiftlab
Ind-Swift Laboratories — Q2 FY27 Earnings Presentation on 6ix